Affordable Access

Access to the full text

Prostate Cancer Immunotherapy—Finally in From the Cold?

Authors
  • Runcie, Karie D.1
  • Dallos, Matthew C.2
  • 1 New York-Presbyterian/Columbia University Medical Center, 177 Fort Washington Avenue, 6GN-435, New York, NY, 10032, USA , New York (United States)
  • 2 New York-Presbyterian/Columbia University Medical Center, 1130 St Nicholas Avenue, Room 321A, New York, NY, 10032, USA , New York (United States)
Type
Published Article
Journal
Current Oncology Reports
Publisher
Springer-Verlag
Publication Date
Jun 14, 2021
Volume
23
Issue
8
Identifiers
DOI: 10.1007/s11912-021-01084-0
Source
Springer Nature
Keywords
Disciplines
  • Topical Collection on Genitourinary Cancers
License
Yellow

Abstract

Purpose of ReviewDespite significant progress, patients with metastatic prostate cancer continue to have poor prognosis. Immunotherapy has revolutionized cancer care for many tumor types but has a limited role in the treatment of prostate cancer. This review discusses the promise of immunotherapy in prostate cancer treatment with an emphasis on emerging therapeutic targets.Recent FindingsMost prostate tumors have low tumor mutational burden and lack immunogenicity, representing significant hurdles to induction of anti-tumor immunity. However, recent research centered on deciphering key mechanisms of immune resistance in the prostate tumor microenvironment has led to the discovery of a range of new treatment targets. These discoveries are currently being translated into innovative immunotherapy clinical trials for patients with prostate cancer. Recent progress includes early evidence of activity for these novel approaches and the identification of potential predictive biomarkers of response.SummaryNovel treatment strategies using new antigen-directed therapies, drugs targeting the immunosuppressive tumor microenvironment, and combination immunotherapy therapies show great potential and are currently in clinical development. In addition, a deeper understanding of predictors of response and resistance to immunotherapy in prostate cancer is allowing for a more personalized approach to therapy.

Report this publication

Statistics

Seen <100 times